Navigation Links
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
Date:2/26/2013

tic functions required for the proliferation of cancer cells, and tipiracil hydrochloride (TPI), an inhibitor of thymidine phosphorylase (which degrades FTD) that maintains an effective blood concentration of FTD. TAS-102 is administered twice daily to achieve a total daily dose of 70mg/square meter for five days followed by two days of rest and then repeated a second time. This is followed by a 14-day rest period to make a 28-day schedule for one course.

About TAS-102 Phase II Clinical Trial
The Phase II clinical trial was conducted with the participation of 172 patients at 20 medical institutions in Japan from August 2009 to April 2010. The target for the study is an area for which there is currently no fully established therapy in Japan -- specifically, patients refractory to standard chemotherapy for metastatic colorectal cancer who have received at least two or more regimens containing fluoropyrimidine, irinotecan, and oxaliplatin. Patients were randomly assigned TAS-102 (114 cases) or a placebo (58 cases). The primary endpoint was overall survival.

About Global Phase III Clinical Trial (RECOURSE)
The Global Phase III Clinical Trial (RECOURSE) is a randomized, double-blind comparative study of TAS-102 versus a placebo. It is a global Phase III clinical trial that is scheduled to enroll a total of 800 patients from Japan, North America, Europe, and Australia. Patient enrollment began in June 2012. The subjects are patients with unresectable, advanced, recurrent colorectal cancer that is refractory to standard chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and EGFR monoclonal antibody in cases of KRAS wild-type tumor). The trial will compare patients randomly assigned to receive TAS-102 or placebo in order to investigate the efficacy and safety of TAS-102. The p
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
2. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
3. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
5. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
6. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
7. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
8. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
9. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
10. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
11. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
(Date:3/2/2015)... 2, 2015  Akron Children,s Hospital has been designated ... American College of Radiology (ACR), making it the first ... second children,s hospital in the United States ... "Earning recognition from the ACR as a DICOE provides ... level compared with national benchmarks," says Dr. Michael ...
(Date:3/2/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, ... Allowance from the U.S. Patent and Trademark Office ... Compositions and methods to improve the therapeutic benefit ...
Breaking Medicine Technology:Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4
... NEW YORK, March 21, 2011 The Alzheimer,s Drug ... grant of $170,750 to ADispell Inc. to develop small ... loss that occurs with Alzheimer,s Disease. ... licensed technology from Cornell University to develop neuroprotective drug ...
... LLC , ( www.curemark.com ), a drug research and development ... the company has completed its targeted enrollment of Phase III ... Curemark has reached its targeted enrollment for the study ... CM-AT Phase III trial at 18 sites across the country. ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease 2Curemark Completes Enrollment of Phase III Autism Trials 2
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
(Date:3/2/2015)... The minimally invasive surgical instruments market ... 6.1% to reach $14,133.0 million by 2019 from ... as advantages of minimally invasive surgeries over traditional ... invasive surgeries and increasing number of surgical procedures ... minimally invasive surgical instruments market. , For More ...
(Date:3/2/2015)... Houston, TX (PRWEB) March 02, 2015 ... a lot easier thanks to the success of ... making meal planning easy and delicious for thousands ... overwhelmingly positive customer feedback by expanding to offer ... Traditional Tastes, which features seasonally appropriate classic recipes ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
(Date:3/2/2015)... 2015 What are the best practices ... references? When are interviews scheduled, how can physicians best ... training and practicing physicians who are looking for new ... more at the PracticeLink Physician Career Advancement Workshop and ... Fair is from 5:30 to 8:30 p.m. at the ...
Breaking Medicine News(10 mins):Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... 11 Nordic Naturals announces,their new Spa Collection, ... formulas: Omega Radiance(TM) and Omega Therapi(TM). Based on,Norwegian ... the hair and skin with omega-3 and omega-6 ... optimal results. Omega-3s and omega-6s,are considered essential because ...
... from Caring.com, baby boomers caring for an aging parent are playing an ... , ... San Mateo, Calif. (PRWEB) November 11, 2008 -- According to a ... playing an active role when it comes to decisions about their parents, ...
... RX" documents how an entire era of children ... unprecedented change in Western culture: that of drugging ... ever before, according to the producers. This dynamic ... of the most ,respected names in Hollywood, including ...
... National Alzheimer,s Disease Awareness Month--The Apo E Gene ... Alzheimer,s Disease, and Other Chronic Illnesses. ,THE APO ... in "Health: Diet and Weight Loss" category of ... Book News,The APO E Gene Diet presents an ...
... Launches National Multimedia Project Aimed at Preventing,Treating, and ... 11 Every 21 seconds someone in,America sustains ... more,than 19 percent of military personnel returning from ... mild to severe brain trauma., To view ...
... Inc.,s parent,company, Team Finance LLC (the "Company") today ... 2008., The Company previously announced the decision ... substantially completed the disposal,of this business line during ... accounting guidance, the results of the anesthesia management,business ...
Cached Medicine News:Health News:Nordic Naturals Offers Radiant Beauty From the Inside Out With New Spa Collection of Essential Fatty Acid Supplements 2Health News:Boomers Play an Active Role with Parent's Medication Decisions 2Health News:Kevin P. Miller's Film "Generation RX" Reveals Widespread Ethical Conflicts, Risks of Psychiatric Drugs to Children 2Health News:Kevin P. Miller's Film "Generation RX" Reveals Widespread Ethical Conflicts, Risks of Psychiatric Drugs to Children 3Health News:The Apo E Gene Diet--Preventing, Alzheimer's and Heart Disease, One Patient at a Time 2Health News:The Apo E Gene Diet--Preventing, Alzheimer's and Heart Disease, One Patient at a Time 3Health News:The Apo E Gene Diet--Preventing, Alzheimer's and Heart Disease, One Patient at a Time 4Health News:Video: BrainLine.org Confronts Traumatic Brain Injury Crisis 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 4Health News:Team Finance LLC Announces Third Quarter 2008 Results 5Health News:Team Finance LLC Announces Third Quarter 2008 Results 6Health News:Team Finance LLC Announces Third Quarter 2008 Results 7Health News:Team Finance LLC Announces Third Quarter 2008 Results 8Health News:Team Finance LLC Announces Third Quarter 2008 Results 9
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... cost-effective method of providing patient warming while ... warming tube is ideal for use in ... Radiology. The CSZ Warming Tube is the ... it may be used in almost any ...
... Our patient warming system consists of ... a range of blankets for use ... all clinical applications. Blankets are available ... adult and paediatric sizes and a ...
... is the automated benchtop solution for nucleic ... extensive integrated features and a sample throughput ... the system meets the demanding nucleic acid ... to medium sample throughput., ,The high-quality nucleic ...
Medicine Products: